MENU
PLX
Stock ticker: ASE
PRICE
CHANGE
CAPITALIZATION

Protalix BioTherapeutics (PLX) Ownership - Who owns Protalix BioTherapeutics?

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx... Show more

Profile

Industry
Servicestothe Health Industry
Address
2 University Plaza
Phone
+1 201 696-9345
Employees
208
Web
https://www.protalix.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
202.88M
P/E Ratio
64.75
Total Cash
27.41M
Projected Growth
N/A
Total Debt
5.68M
Revenue
45.67M
Risk (Beta)
0.20
Dividend Yield
N/A
Total Cash/Share
0.35
Total Debt/Equity
N/A
Revenue/Share
0.66 USD as % of share price

Fundamentals

PLX
Capitalization
203M
P/E Ratio
64.75
Risk (Beta)
0.20
Dividend Yield
N/A
Total Cash
27.4M
Total Cash/Share
0.35
Total Debt
5.68M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.66%
Revenue
45.7M
ROE
N/A
Book Value
32.4M
P/B Ratio
4.68
Cash Flow
N/A
Earnings
-0.15
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
74K
Current Ratio
1.98
Current Revenue Per Employee
86341.34
Dividends Per Share - Security
N/A
EBITDA
-6.48M
Float
N/A
Float - Current
N/A
Gross Income Margin
53.37
Revenue To Assets
-12.88
Shares Held By Institutions
10.6M
Shares Outstanding - Current
78M
Total Liabilities
29.1M
Total Volume MTD
N/A
Value
-1
Gain YTD
38.298
View a ticker or compare two or three
PLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of recombinant therapeutic proteins

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Servicestothe Health Industry
Address
2 University Plaza
Phone
+1 201 696-9345
Employees
208
Web
https://www.protalix.com